Wednesday, July 30, 2025
Distribution: (800) 510 0384
Washington DC
New York
Toronto
Press ID  
  • Login
The Hudson Weekly
  • Financial
  • Blockchain
  • Technology
  • Entertainment
  • Lifestyle
  • Arts
  • Health
  • Sports
  • Cybersecurity
No Result
View All Result
  • Financial
  • Blockchain
  • Technology
  • Entertainment
  • Lifestyle
  • Arts
  • Health
  • Sports
  • Cybersecurity
No Result
View All Result
The Hudson Weekly
No Result
View All Result

FDA Accepts BioMarin’s New Drug Application for Vosoritide to Treat Children with Achondroplasia

If approved, 1st Therapy in U.S. for the Treatment of Achondroplasia. PDUFA Action Date is Aug. 20, 2021

Emily Manifold by Emily Manifold
November 18, 2020
in Health
A A
FDA Accepts BioMarin’s New Drug Application for Vosoritide to Treat Children with Achondroplasia

© FDA

Share on FacebookShare on Twitter

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for vosoritide, an investigational, once daily injection analog of C-type Natriuretic Peptide (CNP) for children with achondroplasia, the most common form of disproportionate short stature in humans. This acceptance by the FDA marks the first marketing application accepted for a treatment for achondroplasia in the United States

The Prescription Drug User Fee Act (PDUFA) action date is Aug. 20, 2021. The FDA has informed the company that they are not currently planning to hold an advisory committee meeting to discuss the application.

HudsonNewsroom

Five Reasons You Shouldn’t Be Scared to Go to Rehab

The Power of Wellness and Hormone Balance: Dr. Marlene Roberts Redefines Aging

What They Don’t Tell You About Caring for a Loved One With Dementia

Although the FDA did not identify any filing issues with the NDA, the Agency reiterated a position raised during the Pediatric Advisory Committee (PAC) and Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) held on May 11, 2018 recommending two-year controlled trials in different age groups. BioMarin believes the highly persuasive outcomes from the one-year randomized, double-blind, placebo-controlled Phase 3 trial, coupled with data from the Phase 2 program with up to 5 years of long-term follow-up that has been compared to robust natural history data on growth, offers a rigorous and reliable method to assess whether vosoritide has a durable impact on the rate of endochondral bone growth that ultimately increases final adult height. This information was included in the marketing application.

While not part of the vosoritide marketing application, in Q4, the Company is also expecting to complete enrollment in a Phase 2 randomized, placebo-controlled study of vosoritide in approximately 70 infants and young children with achondroplasia, aged zero to less than 60 months, for a period of 52 weeks. The study will be followed by a subsequent open-label extension trial when all subjects receive active treatment. Children in this study will complete a minimum three-month baseline study to determine their respective baseline growth prior to dosing in the Phase 2 study. Children in this study will have completed a minimum three-month baseline study to determine their respective baseline growth prior to entering the Phase 2 study. The primary objectives of the study are to evaluate safety, tolerability, and the effect of vosoritide on height Z-scores, which is the number of standard deviations in relation to the mean height of age-matched, average stature children. The company also plans to augment the height Z-score data with assessments including proportionality, functionality, quality of life, sleep apnea, and foramen magnum dimension, as well as the advent of major illnesses and surgeries.

“We are looking forward to working with the FDA and other regulatory authorities to evaluate the safety and efficacy of the potentially first pharmacological treatment for children with achondroplasia. In addition to the completed clinical studies included in the application, we have included a natural history study to understand the progression of achondroplasia and medical implications,” said Hank Fuchs, M.D., President Worldwide Research and Development at BioMarin. “Our extensive development program has been focused on addressing the underlying cause of achondroplasia. We continue to respect the community’s range of views around treatment options. We are grateful to the families who have participated in the clinical trials, the advocacy groups from around the world, and the study investigators, all who have been on this journey with us to deliver a treatment choice and contribute to further understanding achondroplasia medically and scientifically.”

“This is important progress that could lead to the first pharmacological treatment of the underlying cause of achondroplasia. As a treating physician, I feel that it is very important that such treatment options become available to families who may want to consider them for their child,” said John A. Phillips III, M.D., Vanderbilt University Medical Center (David T Karzon Professor of Pediatrics) and investigator for the vosoritide clinical program. “The comprehensive clinical program for vosoritide provides scientific and clinical knowledge that focuses on the safety and efficacy of vosoritide and better understanding of the basic cause of achondroplasia, its natural history and treatment.”

“We are hopeful that our community is one step closer to having access to the first therapeutic choice for children and families affected by achondroplasia,” said Munira Haider, co-founder of Growing Stronger. “We advocate for rigorous scientific and medical research to improve the quality of medical care for little people.”

Growing Stronger’s mission is to improve the quality of medical care for people through supporting research. The organization raises nonprofit donations that are granted to researchers focused on dwarfism.

Regulatory Status in the U.S. and Europe

BioMarin previously announced that the European Medicines Agency (EMA) validated the Company’s Marketing Authorization Application. Vosoritide has also received orphan drug designation from the FDA and EMA for the treatment of children with achondroplasia. The Orphan Drug Designation program is intended to advance the evaluation and development of products that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions.

Emily Manifold

Emily Manifold

Newsdesk Assistant Editor

More from HW Newsdesk

Breaking Free From Addiction: Tips and Strategies for Recovery
Health

Five Reasons You Shouldn’t Be Scared to Go to Rehab

July 29, 2025
The Power of Wellness and Hormone Balance: Dr. Marlene Roberts Redefines Aging
Health

The Power of Wellness and Hormone Balance: Dr. Marlene Roberts Redefines Aging

July 25, 2025
How to Aid Your Loved One's Independence With Dementia
Health

What They Don’t Tell You About Caring for a Loved One With Dementia

July 24, 2025

HW Newsroom

Salon Under the Stars: EastWest Collective Unites Cultures, Cuisine, and Classical Music at Hephzibah House NYC
Arts

Salon Under the Stars: EastWest Collective Unites Cultures, Cuisine, and Classical Music at Hephzibah House NYC

by D’Arcy Sardone
July 28, 2025

On July 26, Hephzibah House NYC welcomed a sold-out gathering of 40 guests for the summer salon event hosted by...

Top 10 Interior Designers in the United States: Renowned Professionals to Watch Out for

How to Keep Your Apartment Secure Without Installing Expensive Devices

July 28, 2025
How Core Security Principles Lay the Groundwork for Safe, AI-Powered Clouds

How Core Security Principles Lay the Groundwork for Safe, AI-Powered Clouds

July 28, 2025
Lazarus & Rakim Shatter Boundaries With 'Not to Be Defined': A Historic Hip-Hop Alliance

Lazarus & Rakim Shatter Boundaries With ‘Not to Be Defined’: A Historic Hip-Hop Alliance

July 28, 2025
Amid Industry Shakeups, MyState MLS Quietly Reshapes the Real Estate Landscape

What Every Homeowner Needs to Know About Property Liability

July 28, 2025
Exploring the World of Live Casino Gaming

Online Casino Bonus Guide: Welcome Promotions With Real Money

July 28, 2025
How to Build Structured Workflows That Turn Business Disruptions into Minor Hiccups

How to Build Structured Workflows That Turn Business Disruptions Into Minor Hiccups

July 27, 2025
The Science of Sparkle: How Lab Diamonds Are Made

The Science of Sparkle: How Lab Diamonds Are Made

July 26, 2025
Trailblazers Celebrated at MLB All-Star Week as Women Took Center Stage in Baseball and Softball

Trailblazers Celebrated at MLB All-Star Week as Women Took Center Stage in Baseball and Softball

July 25, 2025
The Power of Wellness and Hormone Balance: Dr. Marlene Roberts Redefines Aging

The Power of Wellness and Hormone Balance: Dr. Marlene Roberts Redefines Aging

July 25, 2025
UFC 319: Du Plessis vs. Chimaev: An MMA Betting Strategy Guide for This Middleweight Title Bout

UFC 319: Du Plessis vs. Chimaev: An MMA Betting Strategy Guide for This Middleweight Title Bout

July 25, 2025
Planning a Fintech App? These Development Companies Are Leading the Way

Planning a Fintech App? These Development Companies Are Leading the Way

July 25, 2025
No Result
View All Result

Headlines

Top 10 Hypoallergenic Dog Breeds for Allergy Sufferers

Why Do Crypto Projects Launch Tokens Before a Product?

California Live Podcast Elevates Economic Discourse With David Kotok

Salon Under the Stars: EastWest Collective Unites Cultures, Cuisine, and Classical Music at Hephzibah House NYC

How to Keep Your Apartment Secure Without Installing Expensive Devices

How Core Security Principles Lay the Groundwork for Safe, AI-Powered Clouds

Trending

Why Injury Tiers Matter When Calculating the Average Personal Injury Settlement
Financial

Why Injury Tiers Matter When Calculating the Average Personal Injury Settlement

by Hayley Chowdhry
July 29, 2025

How can two people suffer similar accidents but walk away with wildly different settlement checks? The answer...

Breaking Free From Addiction: Tips and Strategies for Recovery

Five Reasons You Shouldn’t Be Scared to Go to Rehab

July 29, 2025
Top 10 Hypoallergenic Dog Breeds for Allergy Sufferers

Top 10 Hypoallergenic Dog Breeds for Allergy Sufferers

July 29, 2025
Why Do Crypto Projects Launch Tokens Before a Product

Why Do Crypto Projects Launch Tokens Before a Product?

July 29, 2025
California Live Podcast Elevates Economic Discourse With David Kotok

California Live Podcast Elevates Economic Discourse With David Kotok

July 29, 2025
  • Kia America представляет цены и захватывающие обновления для Sorento 2025 (ICE)

https://madisongraph.com/kia-america-unveils-pricing-and-exciting-updates-for-2025-sorento-ice/

#nyc #losangeles #chicago #houston #phoenix #philadelphia #sandiego #dallas #sanfrancisco #seattle #denver #washingtondc #boston #detroit #vancouver #toronto #publicrelations #marketingagency #earnedmedia #editorial #marketing #guestpost #guestposting #sponsored #sponsoredpost
  • Kia Recognized as One of TIME Magazine’s “World’s Most Sustainable Companies of 2024”

https://madisongraph.com/kia-recognized-as-one-of-time-magazines-worlds-most-sustainable-companies-of-2024/

#nyc #losangeles #chicago #houston #phoenix #philadelphia #sandiego #dallas #sanfrancisco #seattle #denver #washingtondc #boston #detroit #vancouver #toronto #publicrelations #marketingagency #earnedmedia #editorial #marketing #guestpost #guestposting #sponsored #sponsoredpost
  • VinFast Auto Establishes Dealer Advisory Board to Enhance Customer Experience

https://madisongraph.com/vinfast-auto-establishes-dealer-advisory-board-to-enhance-customer-experience/

#nyc #losangeles #chicago #houston #phoenix #philadelphia #sandiego #dallas #sanfrancisco #seattle #denver #washingtondc #boston #detroit #vancouver #toronto #publicrelations #marketingagency #earnedmedia #editorial #marketing #guestpost #guestposting #sponsored #sponsoredpost
  • Medicare Announces Expansion of Coverage for Microprocessor-Controlled Knees for Lower Mobility Users

https://lincolncitizen.com/medicare-announces-expansion-of-coverage-for-microprocessor-controlled-knees-for-lower-mobility-users/

#nyc #losangeles #chicago #houston #phoenix #philadelphia #sandiego #dallas #sanfrancisco #seattle #denver #washingtondc #boston #detroit #vancouver #toronto #publicrelations #marketingagency #earnedmedia #editorial #marketing #guestpost #guestposting #sponsored #sponsoredpost
  • GA-ASI Successfully Tests PT6 Engine on MQ-9B SkyGuardian Aircraft

https://lincolncitizen.com/ga-asi-successfully-tests-pt6-engine-on-mq-9b-skyguardian-aircraft/

#nyc #losangeles #chicago #houston #phoenix #philadelphia #sandiego #dallas #sanfrancisco #seattle #denver #washingtondc #boston #detroit #vancouver #toronto #publicrelations #marketingagency #earnedmedia #editorial #marketing #guestpost #guestposting #sponsored #sponsoredpost
  • U.S. Leading Economic Index Declines by 0.2% in June 2024, Coincident Index Rises by 0.3%

https://fairmontpost.com/u-s-leading-economic-index-declines-by-0-2-in-june-2024-coincident-index-rises-by-0-3/

#nyc #losangeles #chicago #houston #phoenix #philadelphia #sandiego #dallas #sanfrancisco #seattle #denver #washingtondc #boston #detroit #vancouver #toronto #publicrelations #marketingagency #earnedmedia #editorial #marketing #guestpost #guestposting #sponsored #sponsoredpost
  • USTDA Director Travels to Bulgaria and Romania to Promote Clean, Secure Energy

https://belmontstar.com/ustda-director-travels-to-bulgaria-and-romania-to-promote-clean-secure-energy/

#nyc #losangeles #chicago #houston #phoenix #philadelphia #sandiego #dallas #sanfrancisco #seattle #denver #washingtondc #boston #detroit #vancouver #toronto #publicrelations #marketingagency #earnedmedia #editorial #marketing #guestpost #guestposting #sponsored #sponsoredpost
  • Police Recommend a Hidden Camera Detector Device to Protect Privacy

https://marketsherald.com/police-recommend-a-hidden-camera-detector-device-to-protect-privacy/

#nyc #losangeles #chicago #houston #phoenix #philadelphia #sandiego #dallas #sanfrancisco #seattle #denver #washingtondc #boston #detroit #vancouver #toronto #publicrelations #marketingagency #earnedmedia #editorial #marketing #guestpost #guestposting #sponsored #sponsoredpost

© 2025 The Hudson Weekly. Published by The Ritz Herald. Editions: Markets Herald • Lincoln Citizen • Madison Graph • Belmont Star • Fairmont Post

Address: 1177 6th Avenue, 5th Floor, New York, NY 10036. Removals: pr@hudsonweekly.com. Phone: (718) 313-5252. M-F: 9AM-5PM. Privacy Policy

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

No Result
View All Result
  • Financial
  • Blockchain
  • Technology
  • Entertainment
  • Lifestyle
  • Arts
  • Health
  • Sports
  • Cybersecurity

© 2025. The Hudson Weekly